November 13, 2015 : Latest SGLT-2 Inhibitors News

LATEST NEWS

Experts Conclude that Risk-Benefit Ratio Overwhelmingly Favors Continued Use of SGLT-2

Anti-Diabetic Drug and Superior Reduction of Cardiovascular Death in T2DM Patients 

Effects of Diabetes Medications on Heart Complications  

EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners

Christophe Arbet-Engels, MD, Q6: SGLT-2 Safety Profile

There are many studies going on looking at the side effects of medications for every disease state. Most of these occur after the drugs are on the market and more people are using them.

One of the problems that can occur in these postmarking studies is the lack of good controls and patient choices. This means that a lot of great drugs can get a bum rap because of external influences.

The SGLT-2 Inhibitor class is no exception and this month’s special edition looks at what top thought leaders have to say about some of the recent results and how they should affect your prescribing habits.

Sometimes these studies can find positive results as well. Check out our latest article on the effects of these drugs have on reducing cardiovascular death.

Your partner in diabetes care,

Dave Joffe
Editor-in-chief

Diabetes experts conclude diabetes treatment should continue with no changes in current recommendations.

Findings suggest significant reduction in the risk of CV death and all-cause mortality for T2DM patients with a history of CVD.

Reduced risk of heart attacks, strokes, cardiovascular events suggested.

Dr. Christophe Arbet-Engels talks about the empagliflozin studies and the ongoing safety program to identify any safety and side-effect concerns. However, despite reported potential urinary tract and genital infection issues, the large majority of patients of the study’s 14,000 participants didn’t observe any of these effects.